The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the deterioration ... The Royal Brisbane and Women's Hospital Foundation, and the Queensland Brain Institute) and ...

neura.edu.au Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder of the motor neurons in the motor cortex, brainstem and spinal cord. A combination of upper and ...

amyotrophic lateral sclerosis is now commonly referred to as “ALS.” It is a neurological disease that affects motor neurons, the nerve cells in the brain and spinal cord that control breathing ...

Background Amyotrophic lateral sclerosis overlaps aetiologically and genetically with frontotemporal dementia and occurs in both familial and apparently sporadic forms. The most commonly implicated ...

It also develops therapies for various neurological diseases such as amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury and chemotherapy-induced peripheral neuropathy. Nura Bio ...

A 3D model has been developed that accurately replicates the complex structures of cerebral blood vessels, enabling ...

Background Geographical differences in the incidence of amyotrophic lateral sclerosis (ALS) have been reported in the literature but comparisons across previous studies are limited by different ...

An expansion of a hexanucleotide repeat in the C9ORF72 gene can cause ALS. Here, the authors develop a high-fidelity RNA-targeting CRISPR system to suppress the repeat RNA expressed from the ...

Amyotrophic lateral sclerosis is a fatal and progressive disease, characterized by progressive muscles weakness, with consequent loss of physical capacities. Patients become relentlessly immobile and, ...

A new platform for studying neuroinflammatory diseases, utilizing advanced 3D bioprinting technology has been developed.